AGIO
Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc
$AGIO reports strong financial position, revenue growth, and promising pipeline development for Q1 2023 with $5.1 billion cash and 14% increase in net revenue.
Agios Pharmaceuticals, Inc. reported strong Q1 2023 financial results, with $5.1 billion in cash, cash equivalents, and marketable securities, indicating a robust financial position. Its Mitapivat therapy contributed $5.6 million in net revenue, representing a 14% increase from Q4 2022, and its Phase 3 trial of Vorasidenib demonstrated positive pipeline progress. Agios also appointed a new member to its board of directors and published its 2023 ESG report, continuing to prioritize sustainability. The company plans to execute its growth strategy and commercialize Mitapivat globally through partnerships, creating value for investors.
4mo ago
$AGIO